Gilead Sciences, Inc. (GILD) Now Covered by Deutsche Bank AG

Equities researchers at Deutsche Bank AG initiated coverage on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research report issued to clients and investors on Friday, Marketbeat reports. The firm set a “buy” rating and a $79.00 price target on the biopharmaceutical company’s stock. Deutsche Bank AG’s price target would suggest a potential upside of 10.89% from the stock’s previous close.

GILD has been the subject of several other research reports. Zacks Investment Research upgraded shares of Gilead Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 11th. William Blair restated an “outperform” rating on shares of Gilead Sciences in a research note on Friday, June 16th. Jefferies Group LLC restated a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research note on Thursday, April 6th. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $79.63 price objective for the company in a research note on Tuesday, March 7th. Finally, Bank of America Corporation reiterated a “neutral” rating and set a $68.19 target price (down previously from $76.00) on shares of Gilead Sciences in a research note on Monday, March 13th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, fifteen have given a buy rating and two have issued a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and an average target price of $80.90.

Gilead Sciences (NASDAQ:GILD) opened at 71.24 on Friday. The stock has a 50 day moving average price of $65.46 and a 200 day moving average price of $69.00. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $88.85. The stock has a market cap of $93.09 billion, a PE ratio of 7.53 and a beta of 1.20.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.18 by $0.02. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. The company had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.66 billion. On average, analysts predict that Gilead Sciences will post $8.35 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 29th. Investors of record on Friday, June 16th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Wednesday, June 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.92%. Gilead Sciences’s dividend payout ratio (DPR) is currently 21.99%.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by sleekmoney and is the property of of sleekmoney. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://sleekmoney.com/gilead-sciences-inc-gild-now-covered-by-deutsche-bank-ag/1942048.html.

In related news, Director John Francis Cogan sold 9,943 shares of the firm’s stock in a transaction that occurred on Tuesday, May 9th. The shares were sold at an average price of $67.25, for a total transaction of $668,666.75. Following the sale, the director now owns 47,562 shares in the company, valued at $3,198,544.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 30th. The stock was sold at an average price of $67.48, for a total transaction of $337,400.00. Following the sale, the executive vice president now owns 117,988 shares in the company, valued at approximately $7,961,830.24. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 88,276 shares of company stock worth $5,932,578. 1.30% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in the company. Hall Laurie J Trustee raised its stake in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares during the period. Cable Hill Partners LLC raised its stake in shares of Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 541 shares during the period. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares during the period. Dubuque Bank & Trust Co. raised its stake in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares during the period. Finally, Penserra Capital Management LLC raised its stake in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the period. Hedge funds and other institutional investors own 73.99% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/gilead-sciences-inc-gild-now-covered-by-deutsche-bank-ag/1942048.html

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *